Scholar Rock (NASDAQ:SRRK) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Scholar Rock (NASDAQ:SRRK) in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a $58.00 target price on the stock.

SRRK has been the topic of several other reports. Barclays increased their price target on Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Wolfe Research assumed coverage on Scholar Rock in a report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 target price on the stock. UBS Group initiated coverage on Scholar Rock in a research report on Wednesday, January 7th. They set a “buy” rating and a $60.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a research report on Thursday, January 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. Four research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $52.00.

Scholar Rock Stock Performance

SRRK opened at $44.31 on Tuesday. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. Scholar Rock has a 12-month low of $22.71 and a 12-month high of $49.82. The firm has a 50 day moving average of $45.29 and a two-hundred day moving average of $39.08. The firm has a market capitalization of $4.52 billion, a PE ratio of -14.07 and a beta of 0.70.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.10. During the same quarter in the previous year, the company earned ($0.64) earnings per share. On average, analysts anticipate that Scholar Rock will post -2.42 EPS for the current year.

Insiders Place Their Bets

In other news, insider Caryn Parlavecchio sold 9,035 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total transaction of $420,398.55. Following the completion of the transaction, the insider directly owned 169,087 shares of the company’s stock, valued at $7,867,618.11. This represents a 5.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Mo Qatanani sold 8,484 shares of Scholar Rock stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $47.07, for a total transaction of $399,341.88. Following the completion of the sale, the insider directly owned 98,445 shares in the company, valued at $4,633,806.15. This represents a 7.93% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 344,932 shares of company stock valued at $15,371,225 over the last ninety days. 13.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Orbis Allan Gray Ltd raised its stake in Scholar Rock by 1,034.5% during the fourth quarter. Orbis Allan Gray Ltd now owns 3,428,929 shares of the company’s stock worth $151,044,000 after purchasing an additional 3,126,677 shares during the period. Wellington Management Group LLP grew its position in Scholar Rock by 124.5% in the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock worth $169,289,000 after acquiring an additional 2,521,022 shares during the period. Holocene Advisors LP acquired a new stake in Scholar Rock during the third quarter worth $91,670,000. Norges Bank purchased a new stake in Scholar Rock in the fourth quarter valued at $91,603,000. Finally, Siren L.L.C. raised its position in Scholar Rock by 17.0% in the fourth quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock valued at $476,842,000 after purchasing an additional 1,575,008 shares during the period. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).